Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans

BACKGROUND AND OBJECTIVES: Current anticoagulants pose an increased risk of bleeding. The development of drugs targeting factor XIa, like asundexian, may provide a safer treatment option. A human mass‑balance study was conducted to gain a deeper understanding of the absorption, distribution, metabol...

Descripción completa

Detalles Bibliográficos
Autores principales: Piel, Isabel, Engelen, Anna, Lang, Dieter, Schulz, Simone I., Gerisch, Michael, Brase, Christine, Janssen, Wiebke, Fiebig, Lukas, Heitmeier, Stefan, Kanefendt, Friederike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322790/
https://www.ncbi.nlm.nih.gov/pubmed/37365440
http://dx.doi.org/10.1007/s13318-023-00838-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322790/
https://www.ncbi.nlm.nih.gov/pubmed/37365440
http://dx.doi.org/10.1007/s13318-023-00838-4

Ejemplares similares